478 related articles for article (PubMed ID: 34571731)
1. Recent Updates on Mechanisms of Resistance to 5-Fluorouracil and Reversal Strategies in Colon Cancer Treatment.
Azwar S; Seow HF; Abdullah M; Faisal Jabar M; Mohtarrudin N
Biology (Basel); 2021 Aug; 10(9):. PubMed ID: 34571731
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Smorenburg CH; Peters GJ; van Groeningen CJ; Noordhuis P; Smid K; van Riel AM; Dercksen W; Pinedo HM; Giaccone G
Ann Oncol; 2006 Jan; 17(1):35-42. PubMed ID: 16251201
[TBL] [Abstract][Full Text] [Related]
3. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase.
Banerjee D; Mayer-Kuckuk P; Capiaux G; Budak-Alpdogan T; Gorlick R; Bertino JR
Biochim Biophys Acta; 2002 Jul; 1587(2-3):164-73. PubMed ID: 12084458
[TBL] [Abstract][Full Text] [Related]
4. Safety and antitumor activity of arsenic trioxide plus infusional 5-fluorouracil, leucovorin, and irinotecan as second-line chemotherapy for refractory metastatic colorectal cancer: A pilot study from South India.
Lakshmaiah KC; Chaudhuri T; Babu GK; Lokanatha D; Jacob LA; Suresh Babu MC; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(4):631-633. PubMed ID: 30082548
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells.
Yeh KH; Cheng AL; Wan JP; Lin CS; Liu CC
Anticancer Drugs; 2004 Apr; 15(4):371-6. PubMed ID: 15057142
[TBL] [Abstract][Full Text] [Related]
6. Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro.
Deng J; Lei W; Fu JC; Zhang L; Li JH; Xiong JP
Biochem Biophys Res Commun; 2014 Jan; 443(3):789-95. PubMed ID: 24275137
[TBL] [Abstract][Full Text] [Related]
7. Effect of folinic acid on fluorouracil activity and expression of thymidylate synthase.
van der Wilt CL; Pinedo HM; Smid K; Cloos J; Noordhuis P; Peters GJ
Semin Oncol; 1992 Apr; 19(2 Suppl 3):16-25. PubMed ID: 1532671
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to 5-fluorouracil via HSP90/Src-mediated increase in thymidylate synthase expression in colon cancer.
Ahn JY; Lee JS; Min HY; Lee HY
Oncotarget; 2015 Oct; 6(32):32622-33. PubMed ID: 26416450
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
Bidard FC; Tournigand C; André T; Mabro M; Figer A; Cervantes A; Lledo G; Bengrine-Lefevre L; Maindrault-Goebel F; Louvet C; de Gramont A
Ann Oncol; 2009 Jun; 20(6):1042-7. PubMed ID: 19153116
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
[TBL] [Abstract][Full Text] [Related]
11. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
12. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
Moreau LC; Rajan R; Thirlwell MP; Alcindor T
Anticancer Res; 2013 Apr; 33(4):1765-8. PubMed ID: 23564831
[TBL] [Abstract][Full Text] [Related]
13. The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.
Papamichael D
Stem Cells; 2000; 18(3):166-75. PubMed ID: 10840069
[TBL] [Abstract][Full Text] [Related]
14. An overview of adjuvant systemic chemotherapy for colon cancer.
Andre T; de Gramont A;
Clin Colorectal Cancer; 2004 Jun; 4 Suppl 1():S22-8. PubMed ID: 15212702
[TBL] [Abstract][Full Text] [Related]
15. Expression of genes for 5-FU-metabolizing enzymes and response to irinotecan plus 5-FU-leucovorin in colorectal cancer.
Noda E; Maeda K; Inoue T; Nishihara T; Nishiguchi Y; Ohira M; Hirakawa K
Anticancer Res; 2006; 26(6C):4653-8. PubMed ID: 17214322
[TBL] [Abstract][Full Text] [Related]
16. Epithelial-Mesenchymal Transition and MicroRNAs in Colorectal Cancer Chemoresistance to FOLFOX.
Escalante PI; Quiñones LA; Contreras HR
Pharmaceutics; 2021 Jan; 13(1):. PubMed ID: 33429840
[TBL] [Abstract][Full Text] [Related]
17. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma.
Scheithauer W; Kornek GV; Marczell A; Karner J; Salem G; Greiner R; Burger D; Stöger F; Ritschel J; Kovats E; Vischer HM; Schneeweiss B; Depisch D
Br J Cancer; 1998 Apr; 77(8):1349-54. PubMed ID: 9579845
[TBL] [Abstract][Full Text] [Related]
18. Recent studies of 5-fluorouracil resistance in pancreatic cancer.
Wang WB; Yang Y; Zhao YP; Zhang TP; Liao Q; Shu H
World J Gastroenterol; 2014 Nov; 20(42):15682-90. PubMed ID: 25400452
[TBL] [Abstract][Full Text] [Related]
19. The evolving role of oxaliplatin in the management of colorectal cancer.
de Gramont A; Schmoll HJ; Cervantes A; Tournigand C
Colorectal Dis; 2003 Nov; 5 Suppl 3():10-9. PubMed ID: 23573556
[TBL] [Abstract][Full Text] [Related]
20. National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
Wolmark N; Colangelo L; Wieand S
Semin Oncol; 2001 Feb; 28(1 Suppl 1):9-13. PubMed ID: 11273592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
